Investigation launched into Amphastar over possible securities law violations after stock drops 20%.

Johnson Fistel, PLLP is investigating Amphastar Pharmaceuticals and some executives for potential violations of federal securities laws following a significant 20% drop in Amphastar's stock price. The decline came after Amphastar reported a 15% year-over-year revenue decrease for its BAQSIMI product, citing pricing pressures and unexpected discounts. The investigation aims to determine if investors can recover losses caused by these disclosures. Investors who suffered losses are encouraged to contact Johnson Fistel for more information.